Guidance. Clarity. Direction.

Carter, DeLuca & Farrell LLP, a leader in intellectual property law, provides cost-effective services to clients from around the world, protecting innovations in a wide range of technologies.

Throughout the phases of product or brand development, we form a critical part of our clients’ development teams to provide preparation, prosecution and clearance services to maximize protection while navigating through freedom-to-operate challenges. We also provide extensive IP due diligence services and IP asset assimilation to help our clients achieve their business objectives.

Search Attorneys

Mini Attorneys Search

Professional Name:

Practice Areas:

Events

Check back for future events

CAFC Update

IBM v. ZILLOW GROUP, INC. October 17, 2022

IBM sued Zillow for infringement of seven patents, including U.S. Patent No. 9,158,789 (related to coordinated geospatial, list-based and filter-based selection) and U.S. Patent No. 7,187,389 (related to methods of displaying layered data on a spatially oriented display (like a map), based on nonspatial...

IBM sued Zillow for infringement of seven patents, including U.S. Patent No. 9,158,789 (related to...

WEISNER v. GOOGLE LLC October 13, 2022

Mr. Weisner sued Google LLC for infringement, asserting four patents. Google moved to dismiss, arguing 1) that the asserted patent claims are ineligible under 35 U.S.C. § 101 and 2) that Weisner had failed to meet the minimum threshold for plausibly pleading his claim of patent infringement. The district court granted dismissal on both...

Mr. Weisner sued Google LLC for infringement, asserting four patents. Google moved to dismiss, arguing 1) that the asserted patent...

MYLAN PHARMACEUTICALS INC. v. MERCK SHARP & DOHME CORP September 29, 2022

Merck owns U.S. Patent 7,326,708, which describes sitagliptin dihydrogenphosphate, a dipeptidyl peptidase-IV (“DP-IV”) inhibitor, which can be used for treating non-insulin-dependent (i.e., Type 2) diabetes. Mylan petitioned for inter partes review (“IPR”) of the ’708 patent, arguing that certain claims were anticipated by a Merck-owned International Patent publication by Edmondson. The Board held that Mylan failed...

Merck owns U.S. Patent 7,326,708, which describes sitagliptin dihydrogenphosphate, a dipeptidyl peptidase-IV (“DP-IV”) inhibitor, which can be used for treating non-insulin-dependent (i.e.,...